CH Biotech R&D Co's Total Assets for the quarter that ended in Dec. 2025 was NT$3,574 Mil.
During the past 12 months, CH Biotech R&D Co's average Total Assets Growth Rate was 1.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 4.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 15.30% per year.
During the past 13 years, CH Biotech R&D Co's highest 3-Year average Total Assets Growth Rate was 2767.40%. The lowest was 2.00%. And the median was 7.90%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
CH Biotech R&D Co's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
CH Biotech R&D Co Total Assets Related Terms
CH Biotech R&D Co Total Assets Historical Data
* Premium members only.
The historical data trend for CH Biotech R&D Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
CH Biotech R&D Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CH Biotech R&D Co (TPE:6534) has a Total Assets of NT$3,574 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on CH Biotech R&D Co and its competitors.
Is CH Biotech R&D Co's Total Assets too high?
CH Biotech R&D Co's current Total Assets is NT$3,574 Mil. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Total Assets compare to CTVA and CF?
CH Biotech R&D Co's Total Assets of NT$3,574 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for an Agriculture company?
A good Total Assets depends on the Agriculture industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current Total Assets is NT$3,574 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$100.59, compared to a current price of NT$91.00 — trading 9.5% below its estimated fair value. The current Total Assets is NT$3,574 Mil. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Total Assets is NT$3,574 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$91.00 is trading 9.5% below its estimated GF Value™ of NT$100.59.
GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.
Key valuation signals for TPE:6534:
Total Assets: NT$3,574 Mil
GF Value™: NT$100.59 vs. price of NT$91.00 (9.5% below fair value)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score
Get the complete analysis for TPE:6534
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
